Carrick Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
23
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$20M
- Investors
-
14
Carrick Therapeutics General Information
Description
Developer of cancer therapeutics designed to change the treatment of cancer patients and their lives. The company's therapeutics target molecular pathways that drive away aggressive and resistant forms of cancer using innovative mechanisms, enabling patients to get their predictive biomarkers detected and get their treatments started from an early stage.
Contact Information
Website
www.carricktherapeutics.comCorporate Office
- One Marina Park Drive
- Suite 1410
- Boston, MA 02210
- United States
Corporate Office
- One Marina Park Drive
- Suite 1410
- Boston, MA 02210
- United States
Carrick Therapeutics Timeline
Carrick Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Later Stage VC | 16-Oct-2023 | $20M | Completed | Clinical Trials - Phase 2 | ||
| 11. Later Stage VC | 29-Nov-2022 | Completed | Clinical Trials - Phase 2 | |||
| 10. Later Stage VC (Series C) | 03-Mar-2022 | Completed | Clinical Trials - Phase 2 | |||
| 9. Secondary Transaction - Private | 15-Mar-2021 | Completed | Clinical Trials - Phase 2 | |||
| 8. Later Stage VC (Series B2) | 29-Jan-2021 | Completed | Clinical Trials - Phase 2 | |||
| 7. Early Stage VC (Series B1) | 08-Nov-2019 | Completed | Startup | |||
| 6. Secondary Transaction - Private | 01-Mar-2019 | Completed | Startup | |||
| 5. Early Stage VC | 28-Dec-2018 | Completed | Startup | |||
| 4. Early Stage VC (Series A) | 18-Dec-2017 | $20M | $115M | Completed | Startup | |
| 3. Early Stage VC (Series A) | 03-Oct-2016 | $95M | $95M | Completed | Startup |
Carrick Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E Preferred Shares | ||||||||
| Series D Preferred | ||||||||
| Series C | ||||||||
| Series C | ||||||||
| Series B2 | ||||||||
| Series B1 | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Series A | 24,002,052 | $0.000100 | $2.43 | $2.43 | 1x | $2.43 | 21.15% | |
| Series A | 2,057,612 | $0.000100 | $1.94 | $1.94 | 1x | $1.94 | 1.81% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Carrick Therapeutics Comparisons
Industry
Financing
Details
Carrick Therapeutics Competitors (72)
One of Carrick Therapeutics’s 72 competitors is Aro Biotherapeutics, a Venture Capital-Backed company based in Philadelphia, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aro Biotherapeutics | Venture Capital-Backed | Philadelphia, PA | ||||
| Mestag Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Geneos Therapeutics | Venture Capital-Backed | Philadelphia, PA |
Carrick Therapeutics Patents
Carrick Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025006569-A1 | Combinations of estrogen receptor degraders and cdk7 inhibitors for the treatment of cancer | Inactive | 27-Jun-2023 | ||
| US-20240383900-A1 | Substituted pyrazolo [1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and their therapeutic use | Pending | 16-Jun-2021 | ||
| AU-2022294054-A1 | Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and their therapeutic use | Active | 16-Jun-2021 | ||
| AU-2022294054-B2 | Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and their therapeutic use | Active | 16-Jun-2021 | ||
| CA-3219002-A1 | Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and their therapeutic use | Pending | 16-Jun-2021 | C07D487/04 |
Carrick Therapeutics Signals
Carrick Therapeutics Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| B Capital Group | Venture Capital | Minority | ||
| Pfizer | Corporation | Minority | ||
| Rosetta Capital (UK) | Venture Capital | Minority | ||
| Revelation Partners | Venture Capital | Minority | ||
| Nortrust Nominees | Limited Partner | Minority |
Carrick Therapeutics FAQs
-
When was Carrick Therapeutics founded?
Carrick Therapeutics was founded in 2015.
-
Where is Carrick Therapeutics headquartered?
Carrick Therapeutics is headquartered in Boston, MA.
-
What is the size of Carrick Therapeutics?
Carrick Therapeutics has 23 total employees.
-
What industry is Carrick Therapeutics in?
Carrick Therapeutics’s primary industry is Drug Discovery.
-
Is Carrick Therapeutics a private or public company?
Carrick Therapeutics is a Private company.
-
What is the current valuation of Carrick Therapeutics?
The current valuation of Carrick Therapeutics is .
-
What is Carrick Therapeutics’s current revenue?
The current revenue for Carrick Therapeutics is .
-
How much funding has Carrick Therapeutics raised over time?
Carrick Therapeutics has raised $245M.
-
Who are Carrick Therapeutics’s investors?
B Capital Group, Pfizer, Rosetta Capital (UK), Revelation Partners, and Nortrust Nominees are 5 of 14 investors who have invested in Carrick Therapeutics.
-
Who are Carrick Therapeutics’s competitors?
Aro Biotherapeutics, Mestag Therapeutics, Centrose, Inovio Pharmaceuticals, and Geneos Therapeutics are some of the 72 competitors of Carrick Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process